Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
How Much Will The Pompe Disease Market Be Worth By 2029?
The market size for Pompe disease has been experiencing consistent expansion in the past few years. The forecasted progression is from $1.74 billion in 2024 to $1.8 billion in 2025, following a compound annual growth rate (CAGR) of 3.3%. The factors contributing to the growth during the historical period include heightened awareness and diagnoses, incentives and designations for orphan drugs, partnership and research efforts worldwide, as well as patient backing and support organizations.
Strong growth is anticipated in the pompe disease market in the coming years, with projections estimating that it will reach a value of $2.31 billion by 2029, reflecting a compound annual growth rate (CAGR) of 6.5%. Numerous factors are expected to drive this increase during the forecasted period, including ongoing research and development activity, the expansion of newborn screening initiatives, advancements in the field of gene therapy, increasing worldwide investment in rare diseases, a focus on patient-centric drug development, the growing number of clinical trials and research initiatives, and an increased emphasis on personalised medicine within the market. Noteworthy trends likely to continue into the anticipated period encompass product innovation, technological progress, adoption of patient support programs, an increase in the use of telemedicine for patient care, and collaborative efforts to enlarge access programs.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11906&type=smp
What External And Internal Drivers Are Influencing The Pompe Disease Market?
Growing cases of pompe disease are anticipated to drive the expansion of the pompe disease market. Pompe disease, also referred to as glycogen storage disease type II or acid maltase deficiency, is an uncommon genetic disorder marked by the accumulation of glycogen (a multi-chain sugar molecule) in diverse body tissues, primarily in muscles and organs. Pompe disease treatments encompass protein replacement therapy, alglucosidase alfa, and Nexviazyme for intravenous infusion. An escalation in the number of pompe disease patients will boost the pompe disease market growth. For example, in June 2022, as per the European Medicines Agency Highlights, a Europe-based intergovernmental organization, about 224 infantile-onset, 471 juvenile-onset, and 20,490 adult-onset people in Europe exhibit mutations potentially leading to Pompe disease considering the maximum birth incidence of 11.6 per 100,000. Hence, a spike in cases of pompe disease is stimulating the progress of the pompe disease market.
What Segmentation Insights Are Provided In The Pompe Disease Market Research?
The pompe diseasemarket covered in this report is segmented –
1) By Type: Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Form, Other Types
2) By Diagnosis: Blood Test, Genetic Test, Prenatal Test, Other Diagnosis
3) By Route Of Administration: Oral, Parenteral, Other routes Of administrations
4) By Therapy Type: Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Gene Therapy, Other Therapies
5) By End Users: Hospitals Or Clinics, Pharmaceuticals, Researchers, Other End-Users
Subsegments:
1) By Classic Infantile Form: Early-Onset Classic Pompe Disease; Severe Classic Pompe Disease
2) By Non-Classic Infantile Form: Mild Non-Classic Infantile Pompe Disease; Variants of Non-Classic Infantile Form
3) By Late-Onset Form: Adult-Onset Pompe Disease; Juvenile-Onset Pompe Disease
4) By Other Types: Asymptomatic Carriers; Other Rare Variants of Pompe Disease
Which Notable Trends Are Transforming The Pompe Disease Market Outlook?
The prominence of product innovations is a growing trend in the pompe disease market. Many dominant businesses in this market are leveraging innovative approaches to maintain their market standing. For example, US-based biopharmaceutical firm, Amicus Therapeutics, secured FDA approval in September 2023 for Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) 65 mg capsules. This dual drug regimen is tailored for adults who weigh over 40 kg and have late-onset Pompe Disease (LOPD). Pombiliti, a recombinant human GAA enzyme (rhGAA), is designed for enhanced absorption into muscle cells, while Opfolda acts as an enzyme stabilizer to maintain enzyme stability in the bloodstream. This approval by the FDA highlights the importance of breakthroughs in the scientific and medical fields.
Who Are The Leading Companies Driving The Pompe Disease Market?
Major companies operating in the pompe disease market include F. Hoffmann-La Roche AG, Sanofi S.A., Amicus Therapeutics Inc., Sangamo BioSciences Inc., Asklepios BioPharmaceutical Inc., Audentes Therapeutics Inc., Genethon, Maze Therapeutics Inc., Avidity Biosciences Inc., EpiVax Inc., M6P Therapeutics, Oxyrane UK Limited, Valerion Therapeutics LLC, Abeona Therapeutics Inc., BioMarin Pharmaceutical, Genzyme Corporation, Novartis AG, Ultragenyx Pharmaceutical, Aro Biotherapeutics Company, Akashi Therapeutics, Protalix BioTherapeutics, AVROBIO Inc., Catabasis Pharmaceuticals
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/pompe-disease-global-market-report
Which Geographic Regions Are Creating Strong Demand In The Pompe Disease Market?
North America was the largest region in the pompe disease market in 2024. The regions covered in the pompe disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=11906&type=smp
Browse Through More Reports Similar to the Global Pompe Disease Market 2025, By The Business Research Company
Preventive Healthcare Technologies And Services Global Market Report 2025
Healthcare It Integration Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/healthcare-it-integration-global-market-report
Healthcare Interoperability Solutions Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model